GlassScriptPhysician profile
Jaknel Brown
NPI 1184291734
$1,851.92
in general payments reported to CMS, 2019-2025
31 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $422 · 2023: $135 · 2024: $454 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $353.60 | 2024-2025 | Briviact, Nayzilam, Fintepla |
| Catalyst Pharmaceuticals, INC. | $166.43 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $155.96 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $148.92 | 2022 | |
| Neurelis, INC. | $123.94 | 2024-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $121.27 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $99.20 | 2021-2025 | Daybue |
| Sk Life Science, INC. | $67.37 | 2024 | |
| Averitas Pharma INC. | $45.92 | 2025 | Qutenza |
| Avion Pharmaceuticals | $39.39 | 2022 | |
| Merz Pharmaceuticals, LLC | $38.15 | 2021-2022 | |
| Allergan, INC. | $36.04 | 2021 | |
| Neurocrine Biosciences, INC. | $35.47 | 2022 | |
| Tg Therapeutics, INC. | $34.59 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.89 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $28.71 | 2025 | |
| Tanabe Pharma America, INC. | $28.13 | 2021-2022 | |
| Amgen INC. | $27.67 | 2024 | |
| Biogen, INC. | $27.58 | 2025 | Skyclarys |
| Kyowa Kirin, INC. | $26.70 | 2021-2022 | |
| Metacel Pharmaceuticals LLC | $24.28 | 2024 | Ozobax |
| Aquestive Therapeutics, INC. | $23.63 | 2024 | |
| Ns Pharma, INC. | $19.86 | 2024 | Viltepso |
| Ipsen Biopharmaceuticals, INC | $19.64 | 2022 | |
| Abbvie INC. | $19.63 | 2025 | |
| Adamas Pharmaceuticals, INC. | $19.52 | 2021 | |
| Eisai INC. | $19.41 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.85 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $18.29 | 2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2025 | Hyqvia |
| Janssen Biotech, INC. | $14.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaknel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.